Cotinga Pharmaceuticals is intervening in critical pathways employed by cancer cells to escape apoptosis (cell death) that allow them to continue to survive and spread. By targeting the fundamental pathways in cancer survival – including p53 and KRAS as well as other associated pathways – we can develop therapies that prevent cancer cells from thriving and replicating.

Like the breadth of the Cotinga bird species that inspires our name, Cotinga Pharma has the potential to reach a broad spectrum of cancers by targeting key cancer mechanisms, such as p53 and KRAS, with our two most advanced product candidates.